Clinical Trials Logo
  1. Home
  2. Indolent Lymphoma
  3. NCT04957693

Effect of Vegan Diet and Lifestyle Changes on Indolent Lymphoma During Controlled Waiting Period

Indolent Lymphoma Clinical Trial

Official title:
Effect of Vegan Diet and Lifestyle Changes on the Course and Progression of Indolent Lymphoma During Controlled Waiting Period

Clinical Trial Summary

The aim of the present trial is to evaluate the effect of lifestyle changes on the natural history of indolent lymphomas, during the period of watchful waiting. The intervention program is comprised of specifically designed vegan nutrition, physical activity, mostly aerobic, and stress reduction by relaxation and meditation. Outcome results will be followed and analyzed for 3 years, taking into consideration the following parameters - disease burden, specific disease-related symptoms, relevant blood tests, body weight, indicators of well-being. Changes in these parameters will be correlated with the level of compliance and adherence to the intervention program. The results of the trial group of patients will be further compared to the natural history of the disease in a comparable group of patients during their waiting period who were not subject to the above intervention.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04957693
Study type Interventional
Source Tel-Aviv Sourasky Medical Center
Contact Irit Avivi, Prof'
Phone 03-6943782
Email iritavi@tlvmc.gov.il
Status Recruiting
Phase N/A
Start date July 5, 2021
Completion date October 1, 2025
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03261349 - Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma Phase 2
Active, not recruiting NCT03133221 - 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation Phase 2
Recruiting NCT05003141 - PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies Phase 1
Recruiting NCT00687778 - 11C-Acetate PET/CT Non-FDG-Avid Tumors N/A
Recruiting NCT05543070 - Low-dose Radiotherapy in iNHL Phase 2
Active, not recruiting NCT04431635 - Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma Phase 1
Completed NCT00980395 - Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma Phase 2
Terminated NCT00954005 - Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma Phase 1/Phase 2
Active, not recruiting NCT03424603 - Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies Phase 1
Completed NCT01263899 - A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies Phase 2
Recruiting NCT05020678 - NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers Phase 1
Active, not recruiting NCT04806035 - Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia Phase 1